

ESPI Current Report No. 23/2025

Date of preparation: 2025-05-09

Subject: Update of information on the establishment of subsidiaries by Genomtec SA in connection with adaptation to the requirements of the M&A process.

Legal basis: Art. 17 sec. 1 MAR - confidential information.

Report content:

In reference to current report no. 21/2025 in which it was announced that two special purpose vehicles were established, i.e. GMT ID SA and GMT Genomics SA, the Management Board of Genomtec SA (the "Company", "Issuer", "Genomtec") informs that on May 8, 2025, the Company received a positive decision from the National Center for Research and Development regarding the planned organizational changes. The decision of the National Center for Research and Development was preceded by obtaining the consent of the Polish Agency for Enterprise Development (PARP) and obtaining a positive tax interpretation, which states that the contribution of tangible and intangible assets related to the ID product area and the Onco-SNAAT product area as a capital contribution to the special purpose vehicles will be tax neutral for the Company.

The Company has filed the appropriate applications to the National Court Register for the registration of special purpose vehicles. The above actions will result in signing annexes to agreements with institutions providing grants and convening the General Meeting of the Company.

The Company will inform about subsequent important stages related to the implementation of the strategic directions of development of Genomtec in appropriate reports.